Seymour-Pierce has downgraded the developer to “add” from “buy”, maintaining its 233p target. The broker said a recent equity sale provided cash to expand.
Panmure Gordon cut its recommendation to “sell” from “hold”. Analyst Andy Brown pointed to cut forecasts and a lower seven per cent dividend yield.
SINCLAIR IS PHARMA
Jefferies raised its price target to 48p, from 45p. Analyst Tara Raveendran said their 100 year distribution deal with Valeant could add around 10 per cent to revenues.